Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The EHA Research Roadmap: Malignant Lymphoid Diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The EHA Research Roadmap: Normal Hematopoiesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A Comprehensive Analysis of the Erythropoietin-erythroferrone-hepcidin Pathway in Hereditary Hemolytic Anemias

    Research output: Contribution to journalLetterResearchpeer-review

  4. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The EHA Research Roadmap: Malignant Lymphoid Diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diagnosis of Thrombotic Thrombocytopenic Purpura by ADAMTS13 Activity Quantification

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Do partnership dissolutions and living alone affect systemic chronic inflammation? A cohort study of Danish adults

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Humoral response to two doses of BNT162b2 vaccination in people with HIV

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Immune dysregulation has been highlighted as a key player in the pathogenesis of myelodysplastic syndromes (MDS), but little is known about cytokine profiles in patients with unexplained cytopenia with or without mutations in MDS-associated genes (clonal cytopenias of undetermined significance [CCUS] and idiopathic cytopenias of undetermined significance [ICUS], respectively), which often precede MDS. Here, we study the cytokine profiles in 111 patients with ICUS (N = 41), CCUS (N = 30), lower-risk MDS (LR-MDS; N = 22) and higher-risk MDS (HR-MDS; N = 18), and in healthy elderly controls (N = 21). Twenty cytokines were examined in blood plasma at time of diagnosis using Luminex assays and enzyme linked immunosorbent assays. The cytokine levels were compared between patient groups, and in patients versus controls. Associations between cytokines and MDS-associated mutations were evaluated. An aberrant cytokine profile was observed in all patient groups relative to healthy elderly controls. Patients had significantly higher levels of IL-6 (P< 0 .001), tumor necrosis factor α (P < 0.001), IL-10 (P < 0.001), and C-X-C motif chemokine 10 (P < 0.001) and lower levels of transforming growth factor beta 1 (P < 0.001), CCL5/regulated on activation normal T-cell expressed and secreted (P < 0.001), and S100A4 (P < 0.001) compared with healthy controls. Survival was significantly shorter in CCUS and MDS patients with a high systemic inflammatory cytokine load (median overall survival [OS] 21 months) compared with those with low-moderate systemic inflammatory cytokine load (median OS 64 months; P < 0.0001). These data suggest that patients with ICUS and CCUS have cytokine levels as abnormal as in LR-MDS. Indeed, high cytokine levels are present before MDS is diagnosed and cytokine levels are elevated irrespective of the presence or size of the myeloid clones. Cytokines may have a prognostic impact at a very early premalignant stage of myeloid disorders.

Original languageEnglish
JournalHemaSphere
Volume6
Issue number5
Pages (from-to)e0713
ISSN2572-9241
DOIs
Publication statusPublished - May 2022

Bibliographical note

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

ID: 77705437